<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="42">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05160597</url>
  </required_header>
  <id_info>
    <org_study_id>21-001122</org_study_id>
    <secondary_id>NCI-2021-12975</secondary_id>
    <nct_id>NCT05160597</nct_id>
  </id_info>
  <brief_title>Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy</brief_title>
  <official_title>Evaluation of 68Ga-PSMA-11 PET Guided Prostate Biopsy in Men With Suspicion of Clinically Significant Prostate Cancer and Prior Negative/Inconclusive Biopsy: A Prospective Exploratory Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This early phase I trial studies how well an image-guided prostate biopsy using the imaging&#xD;
      agent 68Ga-prostate-specific membrane antigen (PSMA)-11 with a positron emission&#xD;
      tomography/computed tomography (PET/CT) scan works in diagnosing prostate cancer in men with&#xD;
      a prior negative or inconclusive prostate biopsy. PSMA is a protein that is found on the&#xD;
      surface of prostate cancer cells. 68Ga-PSMA-11 is made up of a substance that binds to PSMA&#xD;
      on tumor cells, linked with a radioactive substance that can then be seen on imaging scans&#xD;
      such as PET/CT. 68Ga-PSMA-11 PET/CT-guided biopsy may help improve the detection rate of&#xD;
      prostate cancer. This may help reduce over-diagnosis and over-treatment in men with low-risk&#xD;
      prostate cancer and under-treatment in men with high-risk prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To assess the detection rate of clinically significant prostate cancer (Gleason score 7 or&#xD;
      more) in patients with focal gallium Ga 68 gozetotide (68Ga-PSMA-11) uptake within the&#xD;
      prostate.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      SCREENING PROCEDURE: Patients receive 68Ga-PSMA-11 intravenously (IV) and 50-100 minutes&#xD;
      later, undergo a PET/CT scan. Only patients with 68Ga-PSMA-11 uptake within the prostate&#xD;
      proceed to image-guided biopsy.&#xD;
&#xD;
      IMAGE-GUIDED BIOPSY: Patients undergo experimental image-guided prostate biopsy using PET/CT&#xD;
      images obtained during screening procedure during a standard of care transrectal&#xD;
      ultrasonography guided biopsy (TRUS).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 31, 2022</start_date>
  <completion_date type="Anticipated">July 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2024</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Detection rate of clinically significant prostate cancer</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Defined as the percentage of clinically significant prostate cancer (Gleason score 7 or more) in patients with focal 68Ga-PSMA-11 uptake within the prostate</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Prostate Carcinoma</condition>
  <arm_group>
    <arm_group_label>Diagnostic (68Ga-PSMA-11, image-guided prostate biopsy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SCREENING PROCEDURE: Patients receive 68Ga-PSMA-11 IV and 50-100 minutes later, undergo a PET/CT scan. Only patients with 68Ga-PSMA-11 uptake within the prostate proceed to image-guided biopsy.&#xD;
IMAGE-GUIDED BIOPSY: Patients undergo experimental image-guided prostate biopsy using PET/CT images obtained during screening procedure during a standard of care TRUS.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biopsy of Prostate</intervention_name>
    <description>Undergo image-guided prostate biopsy</description>
    <arm_group_label>Diagnostic (68Ga-PSMA-11, image-guided prostate biopsy)</arm_group_label>
    <other_name>Prostate Biopsy</other_name>
    <other_name>Prostatic Biopsy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Gallium Ga 68 Gozetotide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Diagnostic (68Ga-PSMA-11, image-guided prostate biopsy)</arm_group_label>
    <other_name>(68)Ga labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68)Ga-labeled Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68)Ga-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68)Gallium-PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>(68Ga)Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>68Ga-DKFZ-PSMA-11</other_name>
    <other_name>68Ga-HBED-CC-PSMA</other_name>
    <other_name>68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC</other_name>
    <other_name>68Ga-PSMA</other_name>
    <other_name>68Ga-PSMA-11</other_name>
    <other_name>68Ga-PSMA-HBED-CC</other_name>
    <other_name>[68Ga] Prostate-specific Membrane Antigen 11</other_name>
    <other_name>[68Ga]GaPSMA-11</other_name>
    <other_name>Ga PSMA</other_name>
    <other_name>Ga-68 labeled DKFZ-PSMA-11</other_name>
    <other_name>Ga-68 labeled PSMA-11</other_name>
    <other_name>GA-68 PSMA-11</other_name>
    <other_name>Gallium Ga 68 PSMA-11</other_name>
    <other_name>Gallium Ga 68-labeled PSMA-11</other_name>
    <other_name>GALLIUM GA-68 GOZETOTIDE</other_name>
    <other_name>Gallium-68 PSMA</other_name>
    <other_name>Gallium-68 PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC</other_name>
    <other_name>GaPSMA</other_name>
    <other_name>PSMA-HBED-CC GA-68</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transrectal Ultrasonography Guided Biopsy</intervention_name>
    <description>Undergo standard of care TRUS</description>
    <arm_group_label>Diagnostic (68Ga-PSMA-11, image-guided prostate biopsy)</arm_group_label>
    <other_name>TRUS Biopsy</other_name>
    <other_name>TRUS-Guided Biopsy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men with suspicion of clinically significant prostate cancer with prior inconclusive,&#xD;
             discordant or negative magnetic resonance imaging/ultrasound (MRI/US) fusion prostate&#xD;
             biopsy&#xD;
&#xD;
          -  Scheduled for a repeat transrectal ultrasound (TRUS) prostate biopsy by standard of&#xD;
             care&#xD;
&#xD;
          -  Focal 68Ga-PSMA-11 uptake within the prostate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Negative 68Ga-PSMA-11 uptake within the prostate (screening failure)&#xD;
&#xD;
          -  Age &lt; 18 and &gt; 90 years&#xD;
&#xD;
          -  Recurrent prostate cancer&#xD;
&#xD;
          -  Inability to provide written informed consent&#xD;
&#xD;
          -  Known inability to remain still and lie flat for the duration of the PET/CT (about 30&#xD;
             minutes)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremie Calais</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA / Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wesley Armstrong</last_name>
    <phone>310-206-1146</phone>
    <email>warmstrong@mednet.ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephanie Lira</last_name>
    <phone>310-206-0596</phone>
    <email>StephanieLira@mednet.ucla.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCLA / Jonsson Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jeremie Calais</last_name>
      <email>jcalais@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Jeremie Calais</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 15, 2021</study_first_submitted>
  <study_first_submitted_qc>December 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2021</study_first_posted>
  <last_update_submitted>December 15, 2021</last_update_submitted>
  <last_update_submitted_qc>December 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edetic Acid</mesh_term>
    <mesh_term>Gallium 68 PSMA-11</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

